Clausen initiated the Export Production Project 4 years ago, by starting the construction of these pharmaceutical plants. Because of its features, it will allow to fulfill local productive needs and reach international markets.
The area of 6500 m2 is divided into two different independent plants, located in the same building. Their design guarantees segregation between them and from the environment, ensuring quality in production, sanitary safety for employees and preservation and care of our environment.
Both facilities and the production equipment comply with current regulations in Good Manufacturing Practices, by EMEA (European Union), FDA (United States of America), WHO (World Health Organization) and ISO Standards. The complete Production process complies with our quality policy that bets on ensuring quality products with regards to:

• Security, efficacy, consistency and reliability.
• Continuous training and staff motivation
• Protection of our environment

The new pharmaceutical facility for the production of biotechnological and segregated solid forms will undoubtedly be a milestone in Clausen’s vision as an exporting Enterprise.

This High Tech pharmaceutical plant, together with international commercial agreements, turns this Export Production Project into a unique undertaking.

This facility will export to Latin America and European and Asian markets as well.
Laboratorios Clausen considers human resource as the main pillar to obtain high quality products
Laboratorios Clausen through its enterprising spirit, has built these two new facilities, unique in our region, exclusively dedicated to the manufacture of biotechnology based solutions for injection (recombinant proteins for hemato-oncology and nephrology) and segregated solid forms (immunosuppressant and antiproliferative drugs for transplants).

Laboratorios Clausen is committed to innovation and constant development, to Uruguayan talent and knowledge and to job creation, pursuing an export production Project, pioneer in our country.